MAPT and early-onset autosomal dominant Alzheimer disease: To date, several tau-targeted nanomaterials have been used to deliver drugs for the treatment of AD: Behafarid et al. prepared folic acid-functionalized gold nanoparticles (FA-AuNPs) and Gold-Fe3O4 core–shell nanoparticles (AuFeNPs), which exhibited binding affinity for both tubulin and tau [14]; Shweta et al. [15] found that protein-capped metal nanoparticles could inhibit tau aggregation in Alzheimer’s disease.